We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
AstraZeneca (AZ) and Amgen disclosed that their investigational asthma drug tezepelumab failed to achieve its primary endpoint of reducing dependence on oral corticosteroids while keeping asthma symptoms stable. Read More
The European Commission has approved ViiV Healthcare’s long-acting HIV treatment Vocabria (cabotegravir) for use in combination with Janssen’s Rekambys (rilpivirine) and Edurant (rilpivirine). Read More
The Department of Justice (DOJ) filed a federal civil lawsuit against Walmart Tuesday, alleging that the retailer illegally sold prescription opioids in its pharmacies and contributed to the opioid abuse crisis. Read More
The National Institutes of Health (NIH) has paused enrollment of critically ill COVID-19 patients in a phase 3 trial of various blood thinners, one of three international trials evaluating whether a full or lower dose of anticoagulants in hospitalized COVID-19 patients is more effective. Read More
Malvern, Pa.-based biotech Ocugen and India’s Bharat Biotech have agreed to work together to develop the Indian company’s COVID-19 vaccine for use in the U.S., a product that is already far along in clinical trials. Read More
Vaccine makers are currently evaluating if a new, highly contagious COVID-19 strain identified in the UK could slip past their shots, but Pfizer/BioNTech, Moderna and others are confident their vaccines will protect against the new mutation, which is likely already in the U.S. Read More
In observance of the holiday season, Drug Industry Daily will not be published Thursday, Dec. 24 or Friday, Dec. 25. The next issue will be published Monday, Dec. 28. Read More
French drugmaker Servier is expanding its reach into cancer drugs by acquiring Agios Pharmaceutical’s oncology business in a deal valued at up to $2 billion. Read More
The FDA has placed a clinical hold on uniQure’s entire clinical development program for its investigational gene therapy for hemophilia B after a patient participating in a pivotal phase 3 clinical trial was given a preliminary diagnosis of liver cancer, the company announced Monday. The serious adverse event was included in a mid-December safety report on the trial as being possibly related to the patient’s treatment with the investigational gene therapy, etranacogene dezaparvovec (AMT-061) in October 2019. Read More